Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12215333 | 0.83 | KDM4E (0.47) | CYP1A2CYP3A4MAPTGAAKDM4E | |
| SCHEMBL12215330 | 0.83 | CYP3A4 (0.41) | CYP3A4MAPTGAAKDM4ELMNA | |
| SCHEMBL12215340 | 0.79 | GAA (0.43) | CYP3A4MAPTGAAKDM4ELMNA | |
| SCHEMBL9829849 | 0.78 | CLEC4M (0.56) | CLEC4MDPP4JAK3JAK2CYP1A2 | |
| SCHEMBL12215320 | 0.78 | CYP3A4 (0.41) | CYP1A2CYP3A4CYP2C19MAPTKDM4E | |
| SCHEMBL13555236 | 0.78 | CYP3A4 (0.41) | CYP1A2CYP3A4CYP2C19MAPTGAA | |
| SCHEMBL12215433 | 0.74 | ALDH1A1 (0.43) | CYP3A4MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL397393 | 0.74 | CLEC4M (0.52) | CLEC4MDPP4JAK3JAK2CYP1A2 | |
| SCHEMBL62162 | 0.74 | CLEC4M (0.52) | CLEC4MDPP4JAK3JAK2CYP1A2 | |
| SCHEMBL7291947 | 0.73 | CLEC4M (0.54) | CLEC4MDPP4JAK3JAK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | IDO2, IDO1, INMT | CLEC4M 2379/4885DPP4 1121/4885JAK3 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.